Vertex Pharmaceuticals Incorporated Stock
Equities
VRTX
US92532F1003
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
400.8 USD | -1.02% | +1.95% | -1.51% |
Financials (USD)
Sales 2024 * | 10.72B | Sales 2025 * | 11.74B | Capitalization | 104B |
---|---|---|---|---|---|
Net income 2024 * | 3.86B | Net income 2025 * | 4.44B | EV / Sales 2024 * | 8.08 x |
Net cash position 2024 * | 16.91B | Net cash position 2025 * | 21.28B | EV / Sales 2025 * | 7.01 x |
P/E ratio 2024 * |
26.9
x | P/E ratio 2025 * |
23.4
x | Employees | 5,400 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.89% |
Latest transcript on Vertex Pharmaceuticals Incorporated
1 day | -1.02% | ||
1 week | +1.95% | ||
Current month | -4.13% | ||
1 month | -3.58% | ||
3 months | -6.27% | ||
6 months | +8.50% | ||
Current year | -1.51% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 51 | 17-01-31 | |
Jeffrey Leiden
CHM | Chairman | 68 | 09-07-07 |
Charles Wagner
DFI | Director of Finance/CFO | 55 | 19-04-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 17-06-07 |
Jeffrey Leiden
CHM | Chairman | 68 | 09-07-07 |
Bruce Sachs
BRD | Director/Board Member | 64 | 97-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.67% | 0 M€ | 0.00% | - | |
7.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 400.8 | -1.02% | 806,473 |
24-04-23 | 404.9 | +1.25% | 1,070,343 |
24-04-22 | 399.9 | +1.43% | 1,393,886 |
24-04-19 | 394.3 | +0.20% | 1,342,138 |
24-04-18 | 393.5 | +0.10% | 949,091 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.86% | 22.2B | |
-16.53% | 21.23B | |
-8.49% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B | |
-24.93% | 8.22B |
- Stock Market
- Equities
- VRTX Stock